Weekly Digest – 10-17 Mar 2023 Weekly Digest – 10-17 Mar 2023 March 13, 2023: Nefecon (Delayed-release Budesonide, Oral)/ IgA Nephropathy/ Calliditas: Plans to file for full approval post-Phase 3 data Calliditas believes Phase 3 confirmatory data for Nefecon for […]
Weekly Digest – 10-17 Mar 2023 Weekly Digest – 10-17 Mar 2023 13 Mar 2023: Pfizer acquires Seagen Pfizer will purchase Seagen for $229 per Seagen share in cash, for a total transaction value of about $43 billion; expected to […]
Weekly Digest – 10-17 Mar 2023 Weekly Digest – 10-17 Mar 2023 Mar 10, 2023: Keytruda (Pembrolizumab, IV)/ Metastatic malignant pleural mesothelioma / Merck: Phase 2/3 IND.227/KEYNOTE-483 study met its primary endpoint Merck announced that the KEYNOTE-483 study, evaluating Keytruda […]
Weekly Digest – 10-17 Mar 2023 Weekly Digest – 10-17 Mar 2023 Mar 10, 2023: DAYBUE (trofinetide, oral) / Rett Syndrome / Acadia Pharmaceuticals: FDA approved DAYBUE for Rett syndrome The US FDA has authorized DAYBUE (trofinetide) by Acadia Pharmaceuticals […]
